{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:49:56Z","timestamp":1775227796509,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03766-1","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:19:37Z","timestamp":1772191177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sleep improvement in patients with rheumatoid arthritis treated with upadacitinib in real-world practice: results from the SLEERA study"],"prefix":"10.1186","volume":"28","author":[{"given":"Thomas","family":"H\u00fcgle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heino","family":"Prillwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Godehard","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Kyburz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Dudler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Schmiedeberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Zanisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie D.","family":"Harrer Kuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal S.","family":"Roulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rubbert-Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"11","key":"3766_CR1","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/acr.24369","volume":"73","author":"K Michaud","year":"2021","unstructured":"Michaud K, et al. Systematic literature review of residual symptoms and an unmet need in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(11):1606\u201316.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"3766_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","volume":"36","author":"PC Taylor","year":"2016","unstructured":"Taylor PC, et al. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36(5):685\u201395.","journal-title":"Rheumatol Int"},{"issue":"1","key":"3766_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3766_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3766_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, et al. In vitro and in vivo characterization of the JAK1 selectivity of Upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.","journal-title":"BMC Rheumatol"},{"issue":"11","key":"3766_CR6","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, Double-Blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788\u2013800.","journal-title":"Arthritis Rheumatol"},{"issue":"10139","key":"3766_CR7","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, et al. Safety and efficacy of Upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503\u201312.","journal-title":"Lancet"},{"issue":"10188","key":"3766_CR8","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303\u201311.","journal-title":"Lancet"},{"issue":"10139","key":"3766_CR9","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, et al. Safety and efficacy of Upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513\u201324.","journal-title":"Lancet"},{"issue":"3","key":"3766_CR10","first-page":"726","volume":"42","author":"T Witte","year":"2024","unstructured":"Witte T, et al. The impact of C-reactive protein levels on the effectiveness of Upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study. Clin Exp Rheumatol. 2024;42(3):726\u201335.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"3766_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40744-024-00651-8","volume":"11","author":"L Bessette","year":"2024","unstructured":"Bessette L, et al. Real-World effectiveness of Upadacitinib for treatment of rheumatoid arthritis in Canadian patients: interim results from the prospective observational CLOSE-UP study. Rheumatol Ther. 2024;11(3):563\u201382.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"3766_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/art.1780370107","volume":"37","author":"M Hirsch","year":"1994","unstructured":"Hirsch M, et al. Objective and subjective sleep disturbances in patients with rheumatoid arthritis. A reappraisal. Arthritis Rheum. 1994;37(1):41\u20139.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"3766_CR13","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s10067-015-2875-4","volume":"34","author":"K Loppenthin","year":"2015","unstructured":"Loppenthin K, et al. Sleep quality and correlates of poor sleep in patients with rheumatoid arthritis. Clin Rheumatol. 2015;34(12):2029\u201339.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3766_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12955-016-0550-3","volume":"14","author":"G Guo","year":"2016","unstructured":"Guo G, et al. Sleep quality in Chinese patients with rheumatoid arthritis: contributing factors and effects on health-related quality of life. Health Qual Life Outcomes. 2016;14(1):151.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"3766_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/14737167.2020.1677156","volume":"20","author":"N Kontodimopoulos","year":"2020","unstructured":"Kontodimopoulos N, et al. Disease activity and sleep quality in rheumatoid arthritis: a deeper look into the relationship. Expert Rev Pharmacoecon Outcomes Res. 2020;20(6):595\u2013602.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"3766_CR16","first-page":"44","volume":"6","author":"MA Sariyildiz","year":"2014","unstructured":"Sariyildiz MA, et al. Sleep quality in rheumatoid arthritis: relationship between the disease severity, depression, functional status and the quality of life. J Clin Med Res. 2014;6(1):44\u201352.","journal-title":"J Clin Med Res"},{"key":"3766_CR17","doi-asserted-by":"crossref","unstructured":"Zheng L, Li G, Hou Z. Association between sleep disorders and rheumatoid arthritis in U.S. Adults. Arthritis Res Ther. 2025;28:20.","DOI":"10.1186\/s13075-025-03694-6"},{"issue":"8","key":"3766_CR18","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/anr.1780320806","volume":"32","author":"MW Mahowald","year":"1989","unstructured":"Mahowald MW, et al. Sleep fragmentation in rheumatoid arthritis. Arthritis Rheum. 1989;32(8):974\u201383.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3766_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/PSY.0000000000000363","volume":"79","author":"MF Bjurstrom","year":"2017","unstructured":"Bjurstrom MF, Olmstead R, Irwin MR. Reciprocal relationship between sleep macrostructure and evening and morning cellular inflammation in rheumatoid arthritis. Psychosom Med. 2017;79(1):24\u201333.","journal-title":"Psychosom Med"},{"key":"3766_CR20","doi-asserted-by":"publisher","unstructured":"Katz P, et al. Objectively measured sleep disorders in rheumatoid arthritis and their association with disease activity. Arthritis Care Res (Hoboken). 2025. https:\/\/doi.org\/10.1002\/acr.25685. Epub ahead of print.","DOI":"10.1002\/acr.25685"},{"issue":"11","key":"3766_CR21","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1136\/ard.2008.100271","volume":"68","author":"L Gossec","year":"2009","unstructured":"Gossec L, et al. Elaboration of the preliminary rheumatoid arthritis impact of disease (RAID) score: a EULAR initiative. Ann Rheum Dis. 2009;68(11):1680\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3766_CR22","first-page":"868","volume":"30","author":"J Kirwan","year":"2003","unstructured":"Kirwan J, et al. Outcomes from the patient perspective workshop at OMERACT 6. J Rheumatol. 2003;30(4):868\u201372.","journal-title":"J Rheumatol"},{"issue":"5","key":"3766_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00004650-200309000-00005","volume":"17","author":"C Bourguignon","year":"2003","unstructured":"Bourguignon C, Labyak SE, Taibi D. Investigating sleep disturbances in adults with rheumatoid arthritis. Holist Nurs Pract. 2003;17(5):241\u20139.","journal-title":"Holist Nurs Pract"},{"issue":"9","key":"3766_CR24","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.3899\/jrheum.090362","volume":"36","author":"GA Wells","year":"2009","unstructured":"Wells GA, et al. Assessing quality of sleep in patients with rheumatoid arthritis. J Rheumatol. 2009;36(9):2077\u201386.","journal-title":"J Rheumatol"},{"issue":"2","key":"3766_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, et al. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193\u2013213.","journal-title":"Psychiatry Res"},{"issue":"12","key":"3766_CR26","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s00296-018-4155-5","volume":"38","author":"I Coskun Benlidayi","year":"2018","unstructured":"Coskun Benlidayi I. Sleep impairment: an obstacle to achieve optimal quality of life in rheumatoid arthritis. Rheumatol Int. 2018;38(12):2183\u201392.","journal-title":"Rheumatol Int"},{"issue":"10","key":"3766_CR27","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1136\/ard.2009.119727","volume":"69","author":"G Wells","year":"2010","unstructured":"Wells G, Li T, Tugwell P. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire sleep disturbance scale. Ann Rheum Dis. 2010;69(10):1768\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3766_CR28","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/acr.23004","volume":"69","author":"V Strand","year":"2017","unstructured":"Strand V, et al. Tofacitinib in combination with conventional Disease-Modifying antirheumatic drugs in patients with active rheumatoid arthritis: Patient-Reported outcomes from a phase III randomized controlled trial. Arthritis Care Res (Hoboken). 2017;69(4):592\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"3766_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3899\/jrheum.110617","volume":"39","author":"K Fragiadaki","year":"2012","unstructured":"Fragiadaki K, et al. Sleep disturbances and Interleukin 6 receptor Inhibition in rheumatoid arthritis. J Rheumatol. 2012;39(1):60\u20132.","journal-title":"J Rheumatol"},{"key":"3766_CR30","unstructured":"Current. technical information RINVOQ\u00ae (Upadacitinib) at www.swissmedicinfo.ch."},{"issue":"3","key":"3766_CR31","first-page":"579","volume":"20","author":"DM van der Heijde","year":"1993","unstructured":"van der Heijde DM, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993;20(3):579\u201381.","journal-title":"J Rheumatol"},{"issue":"1","key":"3766_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44\u20138.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3766_CR33","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796\u2013806.","journal-title":"Arthritis Res Ther"},{"key":"3766_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"3766_CR35","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/art.1780381108","volume":"38","author":"R Buchbinder","year":"1995","unstructured":"Buchbinder R, et al. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures\u2019 responsiveness to treatment in a randomized controlled trial. Arthritis Rheum. 1995;38(11):1568\u201380.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"3766_CR36","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1002\/acr.21747","volume":"64","author":"F Tubach","year":"2012","unstructured":"Tubach F, et al. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: results from a prospective multinational study. Arthritis Care Res (Hoboken). 2012;64(11):1699\u2013707.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"3766_CR37","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3899\/jrheum.110392","volume":"38","author":"V Strand","year":"2011","unstructured":"Strand V, et al. It\u2019s good to feel better but it\u2019s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol. 2011;38(8):1720\u20137.","journal-title":"J Rheumatol"},{"issue":"3","key":"3766_CR38","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/art.20048","volume":"50","author":"E Krishnan","year":"2004","unstructured":"Krishnan E, et al. Normative values for the health assessment questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum. 2004;50(3):953\u201360.","journal-title":"Arthritis Rheum"},{"key":"3766_CR39","doi-asserted-by":"crossref","unstructured":"Chalupczak NV, et al. Sleep matters: exploring the link between sleep disturbances and fatigue in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2025;77(11):1368\u201373.","DOI":"10.1002\/acr.25579"},{"issue":"1","key":"3766_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12874-024-02297-0","volume":"24","author":"Z Qin","year":"2024","unstructured":"Qin Z, et al. The gap between statistical and clinical significance: time to pay attention to clinical relevance in patient-reported outcome measures of insomnia. BMC Med Res Methodol. 2024;24(1):177.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"3766_CR41","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia MJ, et al. Clinical practice guideline for the Pharmacologic treatment of chronic insomnia in adults: an American academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307\u201349.","journal-title":"J Clin Sleep Med"},{"issue":"8","key":"3766_CR42","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1210\/jcem.84.8.5894","volume":"84","author":"AN Vgontzas","year":"1999","unstructured":"Vgontzas AN, et al. Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab. 1999;84(8):2603\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"3766_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328.","journal-title":"Annu Rev Med"},{"issue":"2","key":"3766_CR44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3109\/15412555.2012.729622","volume":"10","author":"X Soler","year":"2013","unstructured":"Soler X, Diaz-Piedra C, Ries AL. Pulmonary rehabilitation improves sleep quality in chronic lung disease. COPD. 2013;10(2):156\u201363.","journal-title":"COPD"},{"key":"3766_CR45","doi-asserted-by":"publisher","first-page":"14028","DOI":"10.1038\/npjpcrm.2014.28","volume":"24","author":"LM McDonnell","year":"2014","unstructured":"McDonnell LM, et al. Pulmonary rehabilitation and sleep quality: a before and after controlled study of patients with chronic obstructive pulmonary disease. NPJ Prim Care Respir Med. 2014;24:14028.","journal-title":"NPJ Prim Care Respir Med"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03766-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03766-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03766-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T14:04:02Z","timestamp":1775225042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03766-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3766"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03766-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the International Council on Harmonisation guidelines and the Declaration of Helsinki. The trial protocol was approved by independent ethics committees and institutional review boards. Written informed consent was provided by patients ahead of study screening.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TH received research grants, consultation and\/or speaker honoraria from Abbvie, Eli Lilly, Fresenius Kabi, MSD, GSK, and Pfizer. TH is board member of Atreon. HP received research grants, consultation and\/or speaker honoraria from AbbVie, Amgen, Boehringer, Celgene, Gr\u00fcnenthal, Novartis, Pfizer, Roche, Sanofi-Genzyme, and UCB. GS received research grants, consultation and\/or speaker honoraria from AbbVie. DK received research grants, consultation and\/or speaker honoraria from AbbVie, Janssen, Eli Lilly, Novartis, UCB and Pfizer. JD received research grants, consultation and\/or speaker honoraria from AbbVie, Janssen, Eli Lilly and Novartis. KS has no conflicts of interest\/financial disclosures. LZ received consultation and\/or speaker honoraria from AbbVie, AstraZeneca, Janssen and Novartis. MDHK is an employee of AbbVie and may hold stock or options. PSR is an employee of AbbVie and may hold stock or options. ARR received honoraria for lectures and consulting AbbVie, Amgen, BMS, Galapagos, Lilly, MSD, Pfizer, Roche, Sanofi, and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}